New Approaches to INOCA

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-15

Study Completion Date

2021-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ischemia with non-obstructive coronary arteries (INOCA) is common in patients with angina. INOCA has been associated with an increased risk of death, myocardial infarction, and stroke, particularly in symptomatic subjects. Previous investigations have evidenced the key role of poor glycemic control and diabetes in coronary microvascular dysfunction. Metformin is an old oral antidiabetic drug which is currently used to achieve glycemic control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease

NCT01167231

Diabetes Mellitus

COMPLETED

Cardiovascular Effects of Metformin on Obesity

NCT01910246

Insulin Resistance

WITHDRAWN PHASE4

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

NCT01607450

Type 2 Diabetes Mellitus Healthy

COMPLETED PHASE2/PHASE3

Early Diabetes Intervention Program

NCT01470937

Type 2 Diabetes Mellitus

COMPLETED PHASE4

Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease

NCT01879293

Left Ventriclar Mass

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ischemia with non-obstructive coronary arteries (INOCA) is common in patients with angina. INOCA has been associated with an increased risk of death, myocardial infarction, and stroke, particularly in symptomatic subjects. Coronary microvascular dysfunction, triggering structural remodeling and vasomotor disorders of coronary arterioles, is currently one of the leading hypotheses to explain INOCA pathophysiology. Previous investigations have evidenced the key role of poor glycemic control and diabetes in coronary microvascular dysfunction. Metformin is an old oral antidiabetic drug which is currently used to achieve glycemic control. Also, previous reports evidenced that metformin improves endothelial dysfunction. Nowadays, it is used in prediabetic patients too. In this scenario, we evaluated the role of metformin in reducing the risk of re-hospitalization in INOCA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

New Approaches in INOCA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hyperglycemia/Normoglycemia

No interventions assigned to this group

Treated/No treated

Metformin

Intervention Type DRUG

Metformin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ≥18 years;
* diagnosis of INOCA;
* availability to participate in the study

Exclusion Criteria

* cancer;
* atrial fibrillation or left bundle branch block;
* previous acute coronary syndrome (ACS) or cardiac revascularization; -pregnancy;
* severe heart valve disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No